论文部分内容阅读
目的:探讨卵泡抑素样蛋白1(FSTL1)在前列腺癌骨转移患者中的表达,以及血清FSTL1与机体慢性炎性因子白介素6(IL-6)、细胞生长分化调节相关因子骨形成蛋白6(BMP6)的相关性,探讨血清FSTL1对前列腺癌骨转移的临床应用价值。方法:采用ELISA法测定35例前列腺癌骨转移患者和30例良性前列腺增生(BPH)患者血清FSTL1、IL-6、BMP6水平,并进行相关性分析。结果:前列腺癌骨转移组血清FSTL1的表达水平[(20.23±8.69)μg/L]较BPH组[(35.45±12.35)μg/L]明显降低(P<0.01);血清IL-6、BMP6表达[(23.56±20.17)μg/L、(428.30±178.40)μg/L]较BPH组[(11.21±8.62)μg/L、(293.50±39.72)μg/L]明显增高(P<0.05);前列腺癌骨转移组的血清FSTL1的表达与IL-6、BMP6呈显著负相关,相关系数分别为-0.971、-0.972(P<0.05)。结论:前列腺癌骨转移患者血清FSTL1的表达降低,并且和体内炎症因子、细胞转化因子有关,为临床判断前列腺癌的发生及进展提供了新的生物学标记,为前列腺癌治疗提供了新的生物学靶向分子。
Objective: To investigate the expression of FSTL1 in patients with prostate cancer with bone metastases, and to explore the relationship between the expression of serum FSTL1 and the chronic inflammatory cytokines interleukin-6 (IL-6), bone morphogenetic protein 6 BMP6), to explore the clinical value of serum FSTL1 in bone metastasis of prostate cancer. Methods: The serum levels of FSTL1, IL-6 and BMP6 in 35 patients with prostate cancer bone metastases and 30 patients with benign prostatic hyperplasia (BPH) were measured by ELISA. The correlations were analyzed. Results: Compared with BPH group, the expression of FSTL1 in serum of prostate cancer group was significantly lower than that of BPH group (P <0.01) (23.56 ± 20.17) μg / L, (428.30 ± 178.40) μg / L] were significantly higher than those in BPH group [(11.21 ± 8.62) μg / L, (293.50 ± 39.72) μg / L] The expression of FSTL1 in cancerous bone metastasis group was negatively correlated with IL-6 and BMP6, the correlation coefficients were -0.971 and -0.972, respectively (P <0.05). Conclusion: The expression of FSTL1 in serum of patients with prostate cancer with bone metastases is decreased, and it is related to inflammatory factors and cell transforming factors in vivo. It provides a new biological marker for clinical diagnosis of prostate cancer and provides a new biomarker for the treatment of prostate cancer Learn to target molecules.